0001104659-24-005247.txt : 20240119 0001104659-24-005247.hdr.sgml : 20240119 20240119163425 ACCESSION NUMBER: 0001104659-24-005247 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240117 FILED AS OF DATE: 20240119 DATE AS OF CHANGE: 20240119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Swartz Robin CENTRAL INDEX KEY: 0001909636 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37625 FILM NUMBER: 24546064 MAIL ADDRESS: STREET 1: C/O VOYAGER THERAPEUTICS, INC. STREET 2: 75 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Voyager Therapeutics, Inc. CENTRAL INDEX KEY: 0001640266 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 857-259-5340 MAIL ADDRESS: STREET 1: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 tm243664-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-01-17 0 0001640266 Voyager Therapeutics, Inc. VYGR 0001909636 Swartz Robin C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 Chief Operating Officer 0 Common Stock 2024-01-17 4 S 0 2543 7.15 D 72327 D Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2024. The sales do not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.04 to $7.27, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Includes 3,253 shares of common stock acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan since the date of the reporting person's last Form 4. /s/ Scott MacDonald, as Attorney-in-Fact for Robin Swartz 2024-01-19